Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases - PubMed (original) (raw)

Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases

D A Arenberg et al. J Exp Med. 1996.

Abstract

The success of solid tumor growth and metastasis is dependent upon angiogenesis. Neovascularization within the tumor is regulated, in part, by a dual and opposing system of angiogenic and angiostatic factors. We now report that IP-10, a recently described angiostatic factor, as a potent angiostatic factor that regulates non-small cell lung cancer (NSCLC)-derived angiogenesis, tumor growth, and spontaneous metastasis. We initially found significantly elevated levels of IP-10 in freshly isolated human NSCLC samples of squamous cell carcinoma (SCCA). In contrast, levels of IP-10 were equivalent in either normal lung tissue or adenocarcinoma specimens. The neoplastic cells in specimens of SCCA were the predominant cells that appeared to express IP-10 by immunolocalization. Neutralization of IP-10 in SCCA tumor specimens resulted in enhanced tumor-derived angiogenic activity. Using a model of human NSCLC tumorigenesis in SCID mice, we found that NSCLC tumor growth was inversely correlated with levels of plasma or tumor-associated IP-10. IP-10 in vitro functioned as neither an autocrine growth factor nor as an inhibitor of proliferation of the NSCLC cell lines. Reconstitution of intratumor IP-10 for a period of 8 wk resulted in a significant inhibition of tumor growth, tumor-associated angiogenic activity and neovascularization, and spontaneous lung metastases, whereas, neutralization of IP-10 for 10 wk augmented tumor growth. These findings support the notion that tumor-derived IP-10 is an important endogenous angiostatic factor in NSCLC.

PubMed Disclaimer

Similar articles

• The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.
  Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM. Addison CL, et al. Hum Gene Ther. 2000 Jan 20;11(2):247-61. doi: 10.1089/10430340050015996. Hum Gene Ther. 2000. PMID: 10680839
• Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10).
  Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM. Arenberg DA, et al. Cancer Immunol Immunother. 2001 Dec;50(10):533-8. doi: 10.1007/s00262-001-0231-9. Cancer Immunol Immunother. 2001. PMID: 11776375 Free PMC article.
• IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
  Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. Numasaki M, et al. J Immunol. 2005 Nov 1;175(9):6177-89. doi: 10.4049/jimmunol.175.9.6177. J Immunol. 2005. PMID: 16237115
• Role of C-X-C chemokines as regulators of angiogenesis in lung cancer.
  Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL. Strieter RM, et al. J Leukoc Biol. 1995 May;57(5):752-62. doi: 10.1002/jlb.57.5.752. J Leukoc Biol. 1995. PMID: 7539029 Review.
• The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer.
  Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM. Arenberg DA, et al. J Leukoc Biol. 1997 Nov;62(5):554-62. doi: 10.1002/jlb.62.5.554. J Leukoc Biol. 1997. PMID: 9365108 Review.

Cited by

• Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer.
  Nakanishi T, Imaizumi K, Hasegawa Y, Kawabe T, Hashimoto N, Okamoto M, Shimokata K. Nakanishi T, et al. Cancer Immunol Immunother. 2006 Nov;55(11):1320-9. doi: 10.1007/s00262-006-0133-y. Epub 2006 Feb 2. Cancer Immunol Immunother. 2006. PMID: 16453150 Free PMC article.
• Regulation of tumor growth by IFN-gamma in cancer immunotherapy.
  Beatty GL, Paterson Y. Beatty GL, et al. Immunol Res. 2001;24(2):201-10. doi: 10.1385/IR:24:2:201. Immunol Res. 2001. PMID: 11594457 Review.
• Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
  Sharma S, Batra RK, Yang SC, Hillinger S, Zhu L, Atianzar K, Strieter RM, Riedl K, Huang M, Dubinett SM. Sharma S, et al. Hum Gene Ther. 2003 Nov 1;14(16):1511-24. doi: 10.1089/104303403322495025. Hum Gene Ther. 2003. PMID: 14577913 Free PMC article.
• The parallel lives of angiogenesis and immunosuppression: cancer and other tales.
  Motz GT, Coukos G. Motz GT, et al. Nat Rev Immunol. 2011 Sep 23;11(10):702-11. doi: 10.1038/nri3064. Nat Rev Immunol. 2011. PMID: 21941296
• Improving immune-vascular crosstalk for cancer immunotherapy.
  Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Huang Y, et al. Nat Rev Immunol. 2018 Mar;18(3):195-203. doi: 10.1038/nri.2017.145. Epub 2018 Jan 15. Nat Rev Immunol. 2018. PMID: 29332937 Free PMC article. Review.

References

1. 1. Agents Actions. 1991 Nov;34(3-4):350-7 - PubMed
2. 1. Int J Cancer. 1992 Sep 30;52(3):366-71 - PubMed
3. 1. Crit Rev Immunol. 1992;12(1-2):17-46 - PubMed
4. 1. Biochim Biophys Acta. 1992 Oct 27;1137(2):189-96 - PubMed
5. 1. Science. 1992 Dec 11;258(5089):1798-801 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program